ZOSANO PHARMA Forum: Community User: Lisa

Ist jetzt schon 4% runter gehämmert worden

Ich hoffe das es hoch geht🙈 Sieht sehr dubios aus....

Ja...was soll den passieren?

Ist jemand investiert? Da könnte was passieren... habe leider zu früh gekauft.

Weiß jemand wie lange es dauert eine Zulassung der FDA zu bekommen ?

Mal eingestiegen. Tiefpunkt sollte erreicht sein und hohes Volumen in US

http://ir.zosanopharma.com/news-releases/news-release-details/zosano-pharma-reports-third-quarter-2019-financial-results-and

Zosano Pharma Announces Completion of Pre-NDA Meetings with FDA for Qtrypta™ https://seekingalpha.com/pr/17698506?source=ansh $ZSAN

😁🤙

👋

Zosano Pharma to Present at the Cantor Global Healthcare Conference https://seekingalpha.com/pr/17645013?source=ansh $ZSAN

Moin Hugo, endlich verirrt sich noch einer hierher. 🙏🍾🍾 Herlich Willkommen Zosano Pharma Announces the Presentation of Multiple Positive Datasets from the Qtrypta™ Long-Term Safety Study at the Congress of the International Headache Society - Repeated Dosing of Qtrypta Over the Course of One Year Reaffirms Qtrypta is Effective and Well-Tolerated as an Acute Treatment for Migraine - - Efficacy and Safety Profile Consistent in Sub Analyses of Patients Taking Concurrent Medications- -Company is Preparing for a New Drug Application (NDA) Submission in Q4 2019- https://www.globenewswire.com/news-release/2019/09/09/1912733/0/en/Zosano-Pharma-Announces-the-Presentation-of-Multiple-Positive-Datasets-from-the-Qtrypta-Long-Term-Safety-Study-at-the-Congress-of-the-International-Headache-Society.html

At The Market Offering Was A Bad Move By Zosano Aug. 23, 2019 12:31 PM ETZosano Pharma Corporation (ZSAN) Summary Zosano recently announced an At The Market (ATM) financing to raise $15M. The stock has significantly dropped since the ATM announcement. This article outlines why use of ATM financing is a bad move for the company. https://seekingalpha.com/article/4287598-at-market-offering-bad-move-zosano?source=quotemedia_readmore

Zosano Pharma Announces Upcoming Oral and Poster Presentations at the Congress of the International Headache Society    August 23, 2019 09:00 ET | Source: Zosano Pharma Corporation Oral presentation of the safety and efficacy of QtryptaTM in a long-term safety study for the acute treatment of migraine. Poster on the results of patients’ freedom from pain and most bothersome symptom when taking Qtrypta concurrently with prophylactic anti-CGRP antibodies. Poster on the safety profile of Qtrypta when taken with serotonergic drugs. https://www.globenewswire.com/news-release/2019/08/23/1905997/0/en/Zosano-Pharma-Announces-Upcoming-Oral-and-Poster-Presentations-at-the-Congress-of-the-International-Headache-Society.html

Zosano Pharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update "We have concentrated our efforts on QtryptaTM and are on track for the planned submission of a New Drug Application (NDA) with the FDA in the fourth quarter of this year,” said John Walker, chairman and CEO of Zosano. “We recently presented Migraine-ACT scores that demonstrated Qtrypta’s ability to effectively manage patients’ acute migraines over a period of up to a year. Additionally, we completed an important manufacturing qualification milestone, confirming that we have a robust and reliable manufacturing process in preparation for a potential commercial launch. We are increasingly enthusiastic about offering a new therapy to the millions of migraineurs still searching for a better and consistent treatment for their acute migraine attacks. If approved by the FDA, Qtrypta has the potential to offer faster, more complete and longer lasting clinical benefit to these patients.” Recent Business Highlights Filed an IND to initiate a Phase 2/3 clinical study in Cluster Headache Pre-Clinical and Clinical pre-NDA meeting scheduled for September 2019 for Qtrypta Completed site qualification batches at a contract manufacturing organization for Qtrypta Presented Migraine-ACT Scores for Qtrypta at the American Headache Society (AHS) Annual Scientific Meeting highlighting the effectiveness of Qtrypta in treating migraines Featured in a keynote speech entitled, “A Novel Intracutaneous Microneedle Delivery System for the Acute Treatment of Migraine” at the Pharmaceutics & Advanced Delivery Systems Conference in Paris Financial Results for the Second Quarter Ended June 30, 2019 Zosano reported a net loss for the second quarter of 2019 of $9.4 million, or $0.55 per share on a basic and diluted basis, compared with a net loss of $8.8 million, or $0.75 per share on a basic and diluted basis, for the same quarter in 2018. Research and development expenses for the second quarter of 2019 were $6.6 million, compared with $6.5 million for the same quarter in 2018. The minor increase in R&D of $0.1 million was mainly due to the scale up and technology transfer to our contract manufacturers, which was offset by lower clinical trial costs. General and administrative expenses for the second quarter of 2019 were $2.8 million, compared with $2.3 million in 2018. The increase of $0.5 million was mainly due to consulting and costs in preparation for commercialization. As of June 30, 2019, cash, cash equivalents and marketable securities were $17.7 million, compared with $23.0 million as of December 31, 2018. The second quarter cash position includes $18.5 million in net cash proceeds from a public offering completed in May 2019. https://www.globenewswire.com/news-release/2019/08/14/1902076/0/en/Zosano-Pharma-Reports-Second-Quarter-2019-Financial-Results-and-Provides-Corporate-Update.html Conference Call https://seekingalpha.com/article/4285705-zosano-pharma-corporation-zsan-ceo-john-walker-q2-2019-results-earnings-call-transcript?source=quotemedia_readmore

Zosano Pharma Files IND to Initiate a Phase 2/3 Clinical Study in Cluster Headache https://finance.yahoo.com/news/zosano-pharma-files-ind-initiate-130000687.html